The parasite that causes Chagas disease is transmitted by the ‘kissing bug’ and also by blood transfusion, organ transplantation, and congenitally. The disease is endemic in 21 countries in Latin America, where 70 million people are at risk.
Mycetoma is a neglected tropical disease characterized by deformity and disability with various health and socio-economic impacts on the affected communities. It is endemic in many tropical and subtropical regions, with cases reported globally. Mycetoma is a chronic inflammatory disease caused by true fungi or certain bacteria and hence the classifications eumycetoma and actinomycetoma respectively.
HIV can be transmitted to children during pregnancy, delivery, and through breastfeeding. An estimated 2.6 million children below the age of 15 were living with HIV in 2014, close to 90% of whom were in sub-Saharan Africa.
DNDi has produced a new report on ‘Pioneering ways of working through innovative partnerships – 2002-2015 – The successful development of a fixed dose combination of artesunate plus amodiaquine antimalarial’. This document reviews the development of DNDi’s first-delivered treatment, ASAQ FDC, and forms part of a broader reflection on DNDi’s business model and its lessons learned over a decade after its creation in 2003.
The Drugs for Neglected Diseases initiative (DNDi) has joined Médecins Sans Frontières/Doctors Without Borders (MSF), the Global Alliance for TB Drug Development (TB Alliance), and other not-for-profit public health organizations in calling for amendments to the Food and Drug Administration (FDA) Priority Review Voucher (PRV) programme for neglected diseases.
Nineteen years ago, while playing on the school field, Alsadik Mohamed Musa Omer pricked his foot on a thorn. Like any other 15 year old boy, he continued playing and later cleaned the small wound caused by the thorn. Soon, the thorn prick was forgotten. A few weeks later, however, he developed an infection around the thorn prick that he again ignored. The infection continued growing and soon developed into sores.
The Drugs for Neglected Diseases initiative (DNDi) extends its deepest condolences to the family of Jacques Pinel, who passed away on 14 August 2015.
2015 is the year the malaria community hoped to achieve universal coverage with existing interventions, near zero deaths, and a 75% reduction of global incidence from 2000 levels. The world is edging closer to these ambitious goals – malaria mortality rates fell by approximately 47% worldwide and incidence rates by 26%.
The Japanese Global Health Innovative Technology Fund (GHIT Fund) has invested $4 million in a partnership between Takeda Pharmaceutical Company and DNDi. The partnership is developing a new drug for visceral leishmaniasis based on a promising new series of aminopyrazoles.
Alexandra Heumber, DNDi‘s Head of Policy Affairs, delivered the following statement on behalf of DNDi at the 68th World Health Assembly.
Two fixed-dose artemisinin combination therapies (ACTs) developed by Drugs for Neglected Diseases initiative (DNDi) and partners, artesunate-amodiaquine (ASAQ) and artesunate-mefloquine (ASMQ), will now be managed by MMV’s Access and Product Management team to help maximize their impact for the patients who need them most.
[30 April 2015]
An estimated 3.3 million children under 15 years of age were living with HIV worldwide in 2012. During that one year alone, some 260,000 children were infected with HIV (over 90% of these were in sub-Saharan Africa). A further 210,000 died of the disease, the vast majority before reaching the age of two and without having been diagnosed. Most of these deaths could have been avoided had diagnosis been carried out in the first weeks of infection and treatment immediately commenced. While the absolute number of infants newly infected with HIV is now declining due to international efforts made in prevention of mother to child transmission, the need for paediatric treatment will continue to increase at least until 2020.
Switzerland has contributed greatly to successful malaria control. Despite successes in reducing the number of deaths caused by malaria, it is vital that we continue fighting this deadly disease. The new website of the Swiss Malaria Group shows Swiss engagement.
The Drugs for Neglected Diseases initiative congratulates the team of researchers at the University of Bonn-Hospital for the Memento Research Award 2015. The research group of Prof. Achim Hörauf from the University of Bonn has received this prize awarded by a group of NGOs for their research into the development of a therapy for the neglected disease `lymphatic filariasis`.
About a year ago, Serafín Moreno – a 40-year old miner born and raised in Chocó, in the Colombian Pacific Coast – believed he was about to die. The first lesion appeared on his forehead, and the second on his arm. After a month, the lesions had grown and multiplied, taking over his entire body.
The Consortium for the Control and Elimination of Visceral Leishmaniasis, known as KalaCORE, is a new partnership between the Drugs for Neglected Diseases initiative, the London School of Hygiene and Tropical Medicine, Médecins Sans Frontières and Mott MacDonald. The consortium has been appointed by the Department for International Development (DFID) to tackle Visceral Leishmaniasis (VL) in South Asia and East Africa.
Leishmaniasis is transmitted by the bite of a sand fly. It is a complex disease with over a million new cases occurring every year and 350 million people living at risk worldwide in 98 countries. The disease presents several different forms, the most common of which are visceral leishmaniasis (VL), which is fatal without treatment, and cutaneous leishmaniasis (CL).
Chagas disease is transmitted by the ‘kissing bug’ and also by blood transfusion, organ transplantation and congenital transmission. The disease is endemic in 21 countries in Latin America, where 100 million people are at risk.
Filarial diseases include onchocerciasis (also known as River Blindness), lymphatic filariasis (also known as elephantiasis), and loiasis. They are caused by parasitic worms which are transmitted by insect vectors to humans, mainly in Africa and Southeast Asia. About 168 million people are infected by the three diseases.
Human African trypanosomiasis (HAT), also known as ‘sleeping sickness’, is transmitted by the tsetse fly. While currently its prevalence is declining, HAT is still a threat to millions of people across Sub-Saharan Africa with 83% (2013) of all cases in the Democratic Republic of Congo (DRC).